Pardi, Norbert
Parkhouse, Kaela
Kirkpatrick, Ericka
McMahon, Meagan
Zost, Seth J.
Mui, Barbara L.
Tam, Ying K.
Karikó, Katalin
Barbosa, Christopher J.
Madden, Thomas D.
Hope, Michael J.
Krammer, Florian
Hensley, Scott E.
Weissman, Drew
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI109946, 1R01AI113047, 1R01AI108686, HHSN272201400005C, R01-AI124429, R01-AI084860)
Burroughs Wellcome Fund (Pathogenesis of Infectious Disease Award)
Takeda Pharmaceuticals U.S.A. (New Frontiers)
Article History
Received: 21 December 2017
Accepted: 13 June 2018
First Online: 22 August 2018
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that K.K. and D.W. are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. D.W. and N.P. are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. S.E.H. has received consultancy fee from Lumen, Novavax, and Merck for work unrelated to this report. The remaining authors declare no competing interests.